DE:YP2 Stock Latest News
Company AnnouncementsBioLineRx and Hemispherian Report GLIX1–PARP Inhibitor Synergy in HR-Proficient Ovarian Cancer1w ago6KBLRX
Company AnnouncementsBioLineRx Shareholders Approve Board, Capital and Compensation Moves at 2026 AGM1M ago6KBLRX
Company AnnouncementsBioLineRx and Hemispherian to Showcase GLIX1 Glioblastoma Data and Trial Design at EANO 20261M ago6KBLRX
Company AnnouncementsBioLineRx Earnings Call Highlights GLIX1 Momentum2M agoBLRXCompany AnnouncementsBioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal2M ago6KBLRX
Company AnnouncementsBioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results2M ago6KBLRX
The FlyBioLineRx reports Q2 EPS 0c vs 0c last year2M agoBLRX
Pre-EarningsBLRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?2M agoBLRX
Company AnnouncementsBioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility2M ago6KBLRX
Pre-EarningsIs BLRX a Buy, Before Earnings?2M agoBLRX
Company AnnouncementsBioLineRx and Hemispherian Report GLIX1–PARP Synergy in Ovarian Cancer Model, Plan Trial Expansion3M ago6KBLRX
Company AnnouncementsBioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze4M agoBLRX
Company AnnouncementsBioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend5M ago6KBLRX





